Idorsia Urging DEA to De-Schedule Dual Orexin Receptor Antagonist Class of Insomnia Meds

 Yesterday, a Citizen Petition (CP) was filed on behalf of Idorsia Pharmaceuticals (SIX: IDIA), urging the Drug Enforcement Administration (DEA) to de-schedule the dual orexin receptor antagonist (DORA) class of chronic insomnia medications based on a review of evidence from available data, including post-marketing surveillance data. The CP to de-schedule the DORA class outlines scientific and medical evidence demonstrating that the DORA class has a negligible abuse profile and potential for abuse, lacks non-medical use in the community, lacks physical and psychological dependence, and therefore, should not be a scheduled class under the Controlled Substances Act.

https://www.biospace.com/article/releases/idorsia-files-petition-with-the-drug-enforcement-administration-dea-urging-them-to-de-schedule-dual-orexin-receptor-antagonist-class-of-insomnia-medications/